Eleven Bio readies dry eye drug for pivotal studies
This article was originally published in Scrip
Executive Summary
Eleven Biotherapeutics's first-in-class topical interleukin-1 (IL-1) signalling inhibitor EBI-005 provided statistically significant improvements from baseline in the signs and symptoms of dry eye disease in a Phase Ib/IIa clinical trial.